|
Parexel, a leading global clinical research organization (CRO) has appointed Jim Anthony to the expanded role of chief commercial officer (CCO) and president, Parexel Biotech, further strengthening the company’s customer focus and its ability to drive growth and value. He served as the global leader for Parexel Biotech since its inception in 2019, and most recently as president and global head, Parexel Biotech.
In conjunction with Anthony’s appointment and as part of the company’s long-term succession planning, Conal Burgess, president and global head, Enterprise Partnerships, will transition from his role at Parexel on December 31, 2025.
“Our industry and clinical development are ever-changing. The company’s ability to evolve and innovate to deliver for our customers is more important than ever,” said Peyton Howell, chief executive officer, Parexel.
“The addition of a chief commercial officer further supports this strategic focus as we work to meet our customers’ needs and accelerate our growth objectives. Jim is the ideal person for this expanded role as demonstrated by his exceptional leadership of Parexel Biotech, growing this business from its start in 2019 to where it stands today, contributing approximately half of Parexel’s global revenue. We look forward to his continued leadership and contributions, building on and scaling this success across our entire commercial organization. We also sincerely thank Conal Burgess for his contributions to Parexel’s success, he added.
He brings more than 25 years of pharmaceutical development and CRO experience to his expanded role. He joined Parexel in 2010 as vice president, North America Business Development, and since that time has held various leadership roles of increasing responsibility, including corporate vice president, Enterprise Account Leader, where he directly managed two of the company’s largest pharma customers, and executive vice president and global head, Parexel Biotech, before being appointed as president and global head, Parexel Biotech in 2023.
Anthony will oversee both biotech and pharmaceutical customer strategy and relationships globally, leveraging the company’s comprehensive suite of solutions and industry-leading therapeutic expertise across phase I-IV clinical development to accelerate and advance their life-changing therapies to market.
"By looking more holistically across all of our customers — from large pharma to small, emerging and mid-sized biotechs — we're strongly positioned to fully leverage our strengths, respond to market challenges with greater agility and strengthen our overall approach to accelerate our growth, said Antony.
|